BIIB - First patient set to receive Biogen's Alzheimer's therapy amid concerns over pricing

selvanegra/iStock via Getty Images A 70-year-old male is expected to become the first patient outside of a clinical trial to receive the recently-approved Alzheimer’s therapy Aduhelm developed by Biogen (BIIB) and Eisai (ESALF). The infusion is set to take place in Providence, Rhode Island, at Butler Hospital's Memory and Aging Program where around 100 patients are likely to be good candidates for the drug, according to Reuters. Biogen has set an average price of $56K per year for the drug and the patient has Medicare insurance. The U.S. Centers for Medicare & Medicaid Services has said it will issue more coverage information soon. Though a vast majority of patients will be covered by the federal Medicare health program, most will have to bear 20% of the costs and 10% of them will have no cap on the costs, according to Robert Egge, chief public policy officer at the Alzheimer's Association. "This could further

For further details see:

First patient set to receive Biogen’s Alzheimer’s therapy amid concerns over pricing